A Disease Registry Encompassing the Care of Patients With Multiple Myeloma on Panobinostat (RECOMM)
This study aims to describe current treatment patterns in the real-world setting among patients with multiple myeloma who are initiating treatment with (or changing treatment to) panobinostat and explore the associations with baseline patient characteristics, healthcare resource utilization, and clinical outcomes.
• Willing and able to provide written informed consent
• At least 18 years of age
• Clinical diagnosis of multiple myeloma that meets published diagnostic criteria
• Initiating panobinostat within 60 days of enrollment
• ECOG performance status 0-1
• Availability of documentation from the patient's medical records regarding previous myeloma treatment, response, and duration of response
• Willing and able to complete the PRO questionnaire